Search research articles
Contact Us
Filters
Showing results (241-250 of 265) with videos related to
Page
of 27
Sort By:
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
February 24, 2021
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study
Stacy A Rudnicki, Jinsy A Andrews, Tina Duong, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
November 3, 2021
Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study
Stacy A Rudnicki, Jinsy A Andrews, Tina Duong, et al.
Journal of Personalized Medicine
|
November 24, 2020
Multi-Omics Identifies Circulating miRNA and Protein Biomarkers for Facioscapulohumeral Dystrophy
Christopher R Heier, Aiping Zhang, Nhu Y Nguyen, et al.
Nature Communications
|
November 15, 2024
VSV<sup>∆M51</sup> drives CD8<sup>+</sup> T cell-mediated tumour regression through infection of both cancer and non-cancer cells
Jahanara Rajwani, Daniil Vishnevskiy, Madison Turk, et al.
Neuromuscular Disorders : NMD
|
January 16, 2021
Corrigendum to "Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy" [Neuromuscular Disorders, Vol. 30 (6) 2020, 492-502]
Kathryn R Wagner, Hoda Z Abdel-Hamid, Jean K Mah, et al.
Neurology
|
January 21, 2009
Incidence of acquired demyelination of the CNS in Canadian children
B Banwell, J Kennedy, D Sadovnick, et al.
The Lancet. Neurology
|
March 20, 2024
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Eugenio Mercuri, Juan J Vilchez, Odile Boespflug-Tanguy, et al.
Plos Medicine
|
September 21, 2020
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study
Edward C Smith, Laurie S Conklin, Eric P Hoffman, et al.
JAMA Network Open
|
January 25, 2022
Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial
Jean K Mah, Paula R Clemens, Michela Guglieri, et al.
Cancer Cell
|
September 12, 2018
Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups
Tenley C Archer, Tobias Ehrenberger, Filip Mundt, et al.
Page
of 27
Search research articles
Search
Showing results (241-250 of 265) with videos related to
Sort By:
Page
of 27
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
February 24, 2021
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study
Stacy A Rudnicki, Jinsy A Andrews, Tina Duong, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
November 3, 2021
Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study
Stacy A Rudnicki, Jinsy A Andrews, Tina Duong, et al.
Journal of Personalized Medicine
|
November 24, 2020
Multi-Omics Identifies Circulating miRNA and Protein Biomarkers for Facioscapulohumeral Dystrophy
Christopher R Heier, Aiping Zhang, Nhu Y Nguyen, et al.
Nature Communications
|
November 15, 2024
VSV<sup>∆M51</sup> drives CD8<sup>+</sup> T cell-mediated tumour regression through infection of both cancer and non-cancer cells
Jahanara Rajwani, Daniil Vishnevskiy, Madison Turk, et al.
Neuromuscular Disorders : NMD
|
January 16, 2021
Corrigendum to "Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy" [Neuromuscular Disorders, Vol. 30 (6) 2020, 492-502]
Kathryn R Wagner, Hoda Z Abdel-Hamid, Jean K Mah, et al.
Neurology
|
January 21, 2009
Incidence of acquired demyelination of the CNS in Canadian children
B Banwell, J Kennedy, D Sadovnick, et al.
The Lancet. Neurology
|
March 20, 2024
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Eugenio Mercuri, Juan J Vilchez, Odile Boespflug-Tanguy, et al.
Plos Medicine
|
September 21, 2020
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study
Edward C Smith, Laurie S Conklin, Eric P Hoffman, et al.
JAMA Network Open
|
January 25, 2022
Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial
Jean K Mah, Paula R Clemens, Michela Guglieri, et al.
Cancer Cell
|
September 12, 2018
Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups
Tenley C Archer, Tobias Ehrenberger, Filip Mundt, et al.
Page
of 27